GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK Total Non-current Assets
All assets not expected to be converted to cash within one year.
GSK plcNYSE: GSK
Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Total non-current assets falls 22.9% from a year ago
Total non-current assets stood at £43.91B at the end of Q2 FY2026, down 22.9% from a year earlier and down 26.2% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Total non-current assets amounted to 71.6% of total assets at the end of Q2 FY2026, up 1.4 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -22.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
GBP · from the balance sheet
- Latest · FY2025
- 43.53B GBP
- Year-over-year change
- +2.5%
- 4-year CAGR
- -14.6%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.53B | +2.5% |
| FY2024 | 2024-12-31 | 42.47B | -17.5% |
| FY2023 | 2023-12-31 | 51.45B | +30.7% |
| FY2022 | 2022-12-31 | 39.38B | -51.9% |
| FY2021 | 2021-12-31 | 81.85B | — |
Total Non-current Assets vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -22.9% is the lowest of 10, against a peer median of +10.9%.
- Total non-current assets amounts to 71.6% of total assets for GSK, versus a peer median of 71.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 386.25B DKK | +20.9% | +40.7% | 64.9% | |
| Jun 2026 | $159.77B USD | -1.6% | +4.2% | 79.4% | |
| Sep 2026 | $141.07B USD | +2.1% | +2.8% | 71.5% | |
| Jun 2026 | €97.54B EUR | +10.9% | +1.1% | 75.6% | |
| Jun 2026 | $94.68B USD | +20.7% | +1.9% | 77.6% | |
| Jun 2026 | $93.12B USD | +15.7% | +8.3% | 71.7% | |
| Sep 2026 | $88.32B USD | +4.5% | +4.9% | 73.8% | |
| Jun 2026 | $77.61B USD | +52.0% | +21.8% | 54.5% | |
| Jun 2026 | $60.68B USD | -0.8% | +12.7% | 63.4% | |
| Jun 2026 | £43.91B GBP | -22.9% | +3.4% | 71.6% | |
| Peer median (excluding GSK) | — | +10.9% | +4.9% | 71.7% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.79B | 3.72B | 3.74B | 3.69B | 3.39B |
| Short-term Investments | 82.62M | 4.15B | 2.86B | 21M | 8.98M |
| Net Receivables | 10.88B | 6.22B | 9.44B | 6B | 7.75B |
| Inventory | 7.83B | 5.15B | 7.01B | 5.67B | 5.91B |
| Other Current Assets | 284.44M | 1.1B | 262.61M | 1.23B | 420.26M |
| Total Current Assets | 25.29B | 20.77B | 23.77B | 17B | 17.48B |
| Property, Plant & Equipment (Net) | 14.45B | 9.62B | 12.69B | 10.07B | 10.03B |
| Goodwill | 14.29B | 7.05B | 8.68B | 6.98B | 7.01B |
| Intangible Assets | 40.74B | 14.32B | 18.83B | 15.52B | 16.72B |
| Long-term Investments | 4.29B | (2.61B) | 2.73B | 1.21B | 1.12B |
| Tax Assets | 7.07B | 5.66B | 7.71B | 6.76B | 6.51B |
| Other Non-current Assets | 1B | 5.35B | 808.22M | 1.93B | 2.14B |
| Total Non-current Assets | 81.85B | 39.38B | 51.45B | 42.47B | 43.53B |
| Total Assets | 107.14B | 60.15B | 75.22B | 59.46B | 61.01B |
| Account Payables | 6.14B | 3.87B | 4.74B | 3.46B | 15.35B |
| Short-term Debt | 4.88B | 3.79B | 3.59B | 2.18B | 3.01B |
| Tax Payables | 489M | 471M | 500M | 703M | 0 |
| Deferred Revenue | 415.82M | 0 | 283.01M | 0 | 0 |
| Other Current Liabilities | 17.97B | 14.1B | 15.25B | 14.76B | 2.5B |
| Total Current Liabilities | 32.06B | 22.81B | 26.86B | 21.7B | 21.35B |
| Long-term Debt | 26.76B | 16.19B | 18.04B | 13.7B | 14.68B |
| Deferred Tax Liabilities | 4.82B | 289M | 396.46M | 382M | 290.49M |
| Deferred Revenue (Non-current) | 115.13M | 83M | 323.8M | 165M | 0 |
| Other Non-current Liabilities | 13.38B | 9.83B | 11.95B | 9.5B | 8.69B |
| Total Non-current Liabilities | 46.17B | 27.24B | 32.05B | 24.68B | 23.66B |
| Total Liabilities | 78.23B | 50.05B | 58.91B | 46.38B | 45.02B |
| Common Stock | 1.82B | 1.35B | 1.72B | 1.35B | 1.35B |
| Retained Earnings | 13.26B | 4.36B | 9.23B | 7.8B | 10.19B |
| Accumulated OCI | 869.56M | 0 | 2.04B | 0 | 0 |
| Other Stockholders Equity | 0 | 1.45B | 0 | 1.05B | 1.32B |
| Minority Interest | 8.52B | (502M) | (703.69M) | (585M) | (420.26M) |
| Total Equity | 28.91B | 10.1B | 16.31B | 13.09B | 15.93B |
| Total Debt | 32.74B | 20.99B | 22.97B | 16.99B | 17.69B |
| Net Debt | 26.95B | 17.26B | 19.23B | 13.29B | 14.3B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.